Ongoing CDC Survey of Clinical Laboratories on Surge Testing

On behalf of the Centers for Disease Control and Prevention (CDC) Division of Laboratory Systems, Gryphon Scientific and Abt Associates are conducting a national survey of clinical laboratories to understand whether and how laboratories would choose to participate in surge testing during a public health emergency. Laboratories that are certified to perform moderate and/or high-complexity testing under the Clinical Laboratory Improvement Amendments (CLIA) are being randomly selected for participation in this survey, to ensure that a nationally representative sample of clinical laboratories are surveyed. Laboratories selected for the survey will receive an invitation letter in the mail between January and July 2021. The survey will ask about factors that influence a laboratory’s capability, capacity, and willingness to perform surge testing following a chemical, biological (intentional or natural), or radiological incident. CDC and its public health partners will use the survey data to expand partnerships with the clinical laboratory sector and improve surge testing during the COVID-19 pandemic and future public health emergencies.

Gryphon Scientific is also collaborating with Healthcare Ready, the Association of Public Health Laboratories, the Association of American Medical Colleges, and the National Marrow Donor Program on this survey project. If you have questions about this survey or want to learn about additional opportunities to become involved in the project, please contact ClinicalLabSurvey@gryphonscientific.com.